Novel M3 Muscarinic Acetylcholine Receptor Antagonists

A compound according to formula I herein below:

• wherein
• Ar1 and Ar2, are independently, selected from the group consisting of optionally substituted phenyl and optionally substituted monocyclic heteroaryl;
• W+ is N+R6R7R8, or an optionally substituted saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more quaternary ammonium nitrogens, and optionally contain one or more secondary nitrogens, tertiary nitrogens, O, or S;
• Z− is a pharmaceutically acceptable counter ion, selected from the group consisting of I−, Br−, Cl−, F−, CF3COO−, mesylate, and tosylate;
• X is C(R1)p, or C(O);
• wherein, when X is C(R1)p, m is an interger from 0 to 3;
• when X is C(O), m is 1;
• p is an interger from 0 to 2;
• n is an interger from 0 to 3;
• Y is C(O), S(O)q, HNC(O), or OC(O);
• wherein, q is 1 or 2;
• R1 and R2 are independently selected from the group consisting of hydrogen, optionally substituted C1-C10 alkyl, optionally substituted C3-C10 cycloalkyl, optionally substituted C3-C10 cycloalkyl alkyl, optionally substituted heterocylic, optionally substituted heterocyclicalkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, and optionally substituted heteroaryl alkyl;
• R3 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkenyl, optionally substituted C1-C10 alkyl, optionally substituted C3-C10 cycloalkyl, optionally substituted C3-C10 cycloalkyl alkyl, optionally substituted aryl alkyl, and optionally substituted heteroaryl alkyl;
• wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of halogen, cyano, hydroxy, hydroxy substituted C1-10alkyl, C1-10 alkoxy, S(O)m′ C1-10 alkyl, C(O)R4, C(O)NR4R5;
• C(O)OH;
• S(O)2NR4R5, NHC(O)R4, NHS(O)2R4, C1-10 alkyl, alkenyl, halosubstituted C1-10 alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroaryl alkyl, wherein these aryl or heteroaryl moieties may be substituted one to two times by halogen, hydroxy, hydroxy substituted alkyl, C1-10 alkoxy, S(O)m′ C1-10 alkyl, C1-10 alkyl, or halosubstituted C1-10 alkyl;
• m′ is 0, 1, or 2;
• R4 and R5, are independently, selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl, optionally substituted alkenyl, optionally substituted C3-C10 cycloalkyl, optionally substituted C3-C10 cycloalkyl alkyl, optionally substituted aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, and optionally substituted heteroaryl alkyl;
• or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O, and S;
• and
• R6, R7, and R8, are independently, selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl, optionally substituted alkenyl, optionally substituted C3-C10 cycloalkyl, optionally substituted C3-C10 cycloalkyl alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heterocyclic, and optionally substituted heterocyclicalkyl;
• or R7 and R8 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O, N and S;
• or any other pharmaceutically acceptable salt thereof.